| Literature DB >> 28352284 |
Camila Lopes Cardoso1, Carolina Arrabal Barros1, Cláudia Curra1, Luciana Maria Paes da Silva Ramos Fernandes2, Solange de Oliveira Braga Franzolin3, Joel Santiago Ferreira Júnior3, Carlos César De Antoni1, Marcos Martins Curi4.
Abstract
A retrospective study was conducted of the records and panoramic radiographs of 35 patients treated with bisphosphonates (BP) and diagnosed with MRONJ. Panoramic radiography was used for evaluation, by two examiners, the following findings were subject of search: osteolysis (OT), cortical bone erosion (EC), bone sclerosis focal (FS) and diffuse (DS), bone sequestration (BS), thickening of lamina dura (TD), prominence of the inferior alveolar nerve canal (IAN), persisting alveolar sockets (SK), and the presence of a pathological fracture (PF). Medical information and staging were also recorded in order to correlate with radiographic findings. Bone sclerosis was the most frequent alteration, followed by OT and TD. The mandible was more affected than the maxilla. There was no significant difference between genders or significant correlation between the number of injuries with age and duration of BP usage. Considering the association between the radiographic findings and MRONJ staging, EC was predominant in stage 3 and DS in stage 2. IAN and PF demonstrated greater association with stage 3. In conclusion, the higher the clinical staging, the greater the severity of the bone alteration. Panoramic radiographic examination is a useful screening tool in patients submitted to antiresorptive therapy.Entities:
Year: 2017 PMID: 28352284 PMCID: PMC5352898 DOI: 10.1155/2017/3190301
Source DB: PubMed Journal: Int J Dent ISSN: 1687-8728
Data of 35 patients with MRONJ.
| Patients | Age | Gender | Systemic disease | Bisphosphonate | Treatment (months) | Drug administration | Stage |
|---|---|---|---|---|---|---|---|
| 1 | 45 | Male | Cancer | Aredia | 12 | Intravenous | 3 |
| 2 | 45 | Male | Cancer | Zometa | 20 | Intravenous | 0 |
| 3 | 54 | Female | Cancer | Aredia/Zometa | 84 | Intravenous | 0 |
| 4 | 42 | Male | Cancer | Aredia | 14 | Intravenous | 3 |
| 5 | 54 | Female | Cancer | Zometa | 28 | Intravenous | 1 |
| 6 | 52 | Female | Cancer | Zometa | 8 | Intravenous | 2 |
| 7 | 54 | Female | Cancer | Zometa | 108 | Intravenous | 2 |
| 8 | 68 | Female | Osteoporosis | Fosamax | 80 | Oral | 2 |
| 9 | 52 | Female | Cancer | Zometa | 48 | Intravenous | 1 |
| 10 | 49 | Female | Cancer | Zometa | 18 | Intravenous | 2 |
| 11 | 59 | Female | Cancer | Zometa | 8 | Intravenous | 1 |
| 12 | 39 | Female | Cancer | Zometa | 6 | Intravenous | 2 |
| 13 | 59 | Female | Cancer | Aredia/Zometa | 84 | Intravenous | 2 |
| 14 | 79 | Female | Osteoporosis | Fosamax | 56 | Oral | 2 |
| 15 | 52 | Female | Cancer | Aredia | 26 | Intravenous | 0 |
| 16 | 64 | Female | Cancer | Zometa | 30 | Intravenous | 2 |
| 17 | 74 | Female | Cancer | Zometa | 48 | Intravenous | 2 |
| 18 | 90 | Female | Cancer | Zometa | 12 | Intravenous | 2 |
| 19 | 57 | Female | Cancer | Zometa | 36 | Intravenous | 2 |
| 20 | 66 | Female | Cancer | Zometa | 36 | Intravenous | 2 |
| 21 | 64 | Female | Cancer | Zometa | 72 | Intravenous | 1 |
| 22 | 24 | Male | Cancer | Zometa | 18 | Intravenous | 1 |
| 23 | 77 | Male | Cancer | Zometa | 12 | Intravenous | 2 |
| 24 | 52 | Male | Cancer | Zometa | 22 | Intravenous | 1 |
| 25 | 65 | Female | Cancer | Zometa | 24 | Intravenous | 3 |
| 26 | 95 | Female | Cancer | Bonviva | 36 | Oral | 2 |
| 27 | 67 | Female | Cancer | Zometa | 288 | Intravenous | 2 |
| 28 | 58 | Female | Cancer | Zometa | 30 | Intravenous | 2 |
| 29 | 64 | Female | Cancer | Zometa | 6 | Intravenous | 0 |
| 30 | 50 | Male | Cancer | Zometa | 24 | Intravenous | 3 |
| 31 | 56 | Female | Cancer | Zometa | 24 | Intravenous | 1 |
| 32 | 64 | Female | Cancer | Zometa | 30 | Intravenous | 2 |
| 33 | 65 | Female | Cancer | Zometa | 48 | Intravenous | 2 |
| 34 | 60 | Female | Cancer | Zometa | 48 | Intravenous | 2 |
| 35 | 70 | Male | Cancer | Zometa | 16 | Intravenous | 1 |
Radiographic findings of 35 patients with MRONJ. Osteolysis (OT), erosion of cortical bone (EC), bone sclerosis focal (FS) and diffuse sclerosis (DS), bone sequestration (BS), thickening in the lamina dura (TD), prominence of the inferior alveolar nerve canal (IAN), persisting alveolar sockets (SK), and presence of pathological fracture (PF).
| Patients | Stage | OT | EC | FS | DS | SQ | TD | IAN | SK |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 3 | + | + | − | − | − | + | − | + |
| 2 | 0 | + | − | − | − | − | + | − | − |
| 3 | 0 | + | − | + | − | − | + | − | + |
| 4 | 3 | + | + | + | + | − | − | + | − |
| 5 | 1 | + | − | − | − | − | − | − | + |
| 6 | 2 | + | − | − | + | + | − | + | − |
| 7 | 2 | + | − | + | + | − | + | + | − |
| 8 | 2 | + | + | + | + | + | − | + | + |
| 9 | 1 | + | − | + | − | + | − | − | − |
| 10 | 2 | − | − | + | − | − | + | − | − |
| 11 | 1 | − | − | + | − | − | + | − | − |
| 12 | 2 | − | − | + | + | − | + | + | − |
| 13 | 2 | + | − | + | − | − | + | − | − |
| 14 | 2 | + | + | − | + | + | − | + | + |
| 15 | 0 | + | − | − | − | + | − | − | − |
| 16 | 2 | − | + | + | + | − | + | + | + |
| 17 | 2 | + | − | + | + | − | − | + | − |
| 18 | 2 | + | − | − | + | − | − | + | − |
| 19 | 2 | + | − | + | + | − | + | + | − |
| 20 | 2 | + | + | + | + | − | + | + | − |
| 21 | 1 | + | − | − | − | − | + | − | − |
| 22 | 1 | − | − | + | − | − | − | − | + |
| 23 | 2 | + | − | + | − | − | − | − | − |
| 24 | 1 | + | − | − | − | − | − | − | + |
| 25 | 3 | + | + | − | − | + | − | − | − |
| 26 | 2 | + | + | − | + | − | − | + | − |
| 27 | 2 | − | − | + | + | − | + | + | − |
| 28 | 2 | + | + | + | − | − | + | − | − |
| 29 | 0 | + | + | − | + | − | − | − | − |
| 30 | 3 | + | + | + | − | − | − | − | + |
| 31 | 1 | − | − | − | − | − | + | − | − |
| 32 | 2 | + | − | − | + | + | + | + | + |
| 33 | 2 | + | − | − | + | + | − | + | + |
| 34 | 2 | + | + | + | − | − | + | − | − |
| 35 | 1 | + | − | − | − | + | − | − | + |
|
|
|
|
|
|
|
|
|
|
Number and percentage of radiographic findings in each stage.
| Stage | OT (%) | EC (%) | FS (%) | DS (%) | SQ (%) | TD (%) | IAN (%) | SK (%) | PF (%) |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 4 (100) | 1 (25) | 1 (25) | 1 (25) | 1 (25) | 2 (50) | 0 (0) | 1 (25) | 0 (0) |
| 1 | 5 (62,5) | 0 (0) | 3 (37,5) | 0 (0) | 2 (25) | 3 (37,5) | 0 (0) | 4 (50) | 0 (0) |
| 2 | 15 (78,9) | 7 (36,8) | 13 (68,4) |
| 5 (26,3) | 11 (57,9) |
| 5 (26,3) | 0 (0) |
| 3 | 4 (100) |
| 2 (50) | 1 (25) | 1 (25) | 1 (25) | 1 (25) | 2 (50) |
|
Radiographic findings that presented a significant association with the clinical stage.